Experts break down SOHO 2026 and topics at the meeting that will shape hematologic oncology for the rest of the year.
Commentary|Videos|September 11, 2024
Challenges With CAR T-Cell Therapies in T-Cell Lymphomas
Author(s)Jasmine Zain, MD
Jasmine M. Zain, MD, of City of Hope, discuss challenges in CAR-T therapies in patients with T-cell lymphomas.
Advertisement
Jasmine M. Zain, MD, of City of Hope, discuss challenges in CAR-T therapies in patients with T-cell lymphomas.
Advertisement
Related to this article
MT027, an off-the-shelf B7-H3–directed CAR T-cell therapy, earned FDA fast track designation for recurrent glioblastoma.
The top 5 OncLive TV videos of the week cover insights in ovarian cancer, breast cancer, head and neck cancer, pancreatic cancer, and follicular lymphoma.
Advertisement
Advertisement
Trending on OncLive
1
FDA Approves Camizestrant Plus a CDK4/6 Inhibitor for Emergent ESR1-Mutated HR+, HER2– Advanced Breast Cancer
2
Ivonescimab Meets OS End Point vs Pembrolizumab in First-Line PD-L1+ NSCLC
3
Daraxonrasib Yields Durable Responses in Previously Treated RAS-Mutant NSCLC
4
Novel Analysis Reveals Millions of Life-Years Saved by Blood Cancer Treatments
5